-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-38 Measuring Disease Burden in Myeloid Malignancies/Residual Disease

Program: Scientific Program
Session: Single Cell Analysis of Hematopoietic Development and Clonal Complexity of Malignant Hematopoiesis
Hematology Disease Topics & Pathways:
Clinically relevant
Saturday, December 5, 2020, 9:25 AM-9:30 AM

Konstanze Dohner, MD

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

Disclosures: Dohner: Bristol-Myers Squibb: Research Funding; Pfizer: Research Funding; Sunesis Pharmaceuticals: Research Funding; Abbvie: Consultancy; Daiichi Sankyo: Honoraria; Celgene: Consultancy, Honoraria; Amgen: Consultancy, Research Funding; Astex Pharmaceuticals: Consultancy; Agios: Consultancy; Arog: Research Funding; Roche: Consultancy; Novartis: Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Astellas Pharma: Consultancy; Janssen: Consultancy, Honoraria.

<< Previous Presentation | Next Presentation